Association of triglyceride-glucose index with long-term prognosis in advanced hepatocellular carcinoma patients receiving immunotherapy and targeted therapy

doi:10.3748/wjg.v31.i30.109863

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 30

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (986)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-6) series.

Item

Count

PDF

HTML

323

Figures (1-5)

102

Tables (1-6)

Sum=539

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

114

Download

209

Sum=323

Publishing Process of This Article

Item

Count

Browse

Download

Sum=92

Aug 14, 2025 (publication date) through Aug 31, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Aug 14, 2025; 31(30): 109863
Published online Aug 14, 2025. doi: 10.3748/wjg.v31.i30.109863

Full Size Figure Download Figure

Figure 1 Flow chart depicting the screening of hepatocellular cancer patients who received camrelizumab combined with lenvatinib. PD-1: Programmed cell death protein-1; PD-L1: Programmed death ligand-1; TyG: Triglyceride-glucose.

Citation: Li GC, Yao ZY, Mao HS, Han ZX. Association of triglyceride-glucose index with long-term prognosis in advanced hepatocellular carcinoma patients receiving immunotherapy and targeted therapy. World J Gastroenterol 2025; 31(30): 109863
URL: https://www.wjgnet.com/1007-9327/full/v31/i30/109863.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i30.109863